The top three players leading the U.S. pregnancy product market collectively hold a share of 25% in the overall market, Transparency Market Research (TMR) finds. The largest share of about 10% is held by Expanscience Laboratories, Inc. Its leading brands, Mustela and Piascledine 300, are spread over 97 countries, garnering a remarkable presence and indomitable revenues. Currently, Expanscience Laboratories, Inc. has 808 patents registered around the world, which will give it a competitive advantage over others in the foreseeable future.
E.T Browne Drug Co., Inc. is the next big contender in the overall market with a share of about 8.1%. The unique ingredients used to make effective line of products and the usage of cocoa butter to enhance the quality of products are giving this company the much-needed boost in the vendor landscape. TMR also observed that the third important player in the overall market, Clarins, has been winning a significant share as the company has toiled towards introducing a new treatments for body and face over the past few years. A majority of its luxury products by Clarins are centered around pure plant extracts, which has been a clear choice amongst pregnant women.
“The rise in general fertility rate has been an important driver for the market,” says a TMR analyst. “As the number of pregnancies are expected to go up in the coming years in the U.S. it is also going to make women prone to various pregnancy-related changes, thereby making them potential customers for these products” added the analyst. To reduce the negative impact of changes to the skin during pregnancy such as sagging, stretch marks, and itching the majority of the women are very likely to invest in various pregnancy products.
The indelible impact of advertisements through newspapers, television, magazines, and other forms of media are also likely to create a fertile space for the U.S. pregnancy products market. Analysts anticipate that the stretch mark minimizer will be the popularly sold product in the overall market due to its long-term necessity during the course of pregnancy, affordable pricing, and non-invasive usage. The easy availability of stretch mark minimizers through various distribution channels is also likely to boost the sale of these products.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10661
The safety of pregnancy products has always been a big restraint for this market. For instance, several topical solutions contain retinoids, which is known to cause birth defects if administered orally. However, how much of it is actually absorbed by the skin and what is its exact impact still remain under study.
Several players in this market are trying to develop products that have natural extracts as opposed to synthetic chemicals to mitigate the risk of health problems these products can lead to.
The U.S. pregnancy products market was valued at US$266.6 mn in 2014. However, analysts are projecting that the opportunity of this market will value US$439.2 mn by the end of 2023. To reach this valuation, the market is anticipated to sprint at a pace of 5.7% CAGR between 2015 and 2023. As of 2014, the stretch mark minimizer held a formidable share of 50% in the overall market and is expected to retain this dominance in the coming years as well. The other product segments are anticipated to surge at a CAGR of 6.3% during the forecast period.
The information presented in this review is based on the findings of a report by Transparency Market Research titled “Pregnancy Products Market – U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453